Biomarkers of psychiatric diseases: current status and future prospects

Metabolism. 2015 Mar;64(3 Suppl 1):S11-5. doi: 10.1016/j.metabol.2014.10.026. Epub 2014 Oct 30.

Abstract

Abnormal behavior and disturbed cognition, often assumed to represent psychiatric illness, may actually result from some form of occult organic brain disease that can be detected by means of one or more biomarkers. This truth was discovered more than a century ago by Aloysius Alzheimer, a German psychiatrist and neuropathologist. As a psychiatrist, he described the behavioral manifestations of "senile dementia" in a 51-year-old female; as a neuropathologist, he was the first to recognize the significance of the senile plaques and neurofibrillary tangles found in her brain after her death at age 55 years. It was Alzheimer who made the connection between these "biomarkers" and the symptoms of the increasingly prevalent disease that now bears his name. In recent years, the search for psychiatry-relevant biomarkers of major depression, schizophrenia, bipolar disease, and other important psychiatric/neuropsychiatric disorders has intensified. Biomarkers in psychiatry and neuropsychiatry have the potential of clarifying the etiology of an ambiguous clinical presentation-making it possible, for example, to detect underlying differences between psychological maladies that have confusingly similar symptoms. In addition, attempts are now being made to classify mental disorders on the basis of biomarkers. Biomarkers may also disclose the presence of a previously unsuspected physical explanation for behavior(s) originally presumed to be "psychiatric" in origin. Although clinically usable biomarkers in the diagnosis and treatment of mental illness await validation, candidate genomic biomarkers and protein profiling of candidate biomarkers in psychiatry are rapidly gaining ground as areas of interest, with considerable future potential. This review considers biomarker-related issues germane to psychiatry and neuropsychiatry in the context of new data that can be used to tailor therapies to the individual psychiatric patient.

Keywords: Bipolar disorder; Depression; Schizophrenia; Suicidality.

Publication types

  • Historical Article
  • Review

MeSH terms

  • Acetyltransferases / blood
  • Alzheimer Disease / diagnosis
  • Alzheimer Disease / history
  • Biomarkers*
  • Bipolar Disorder / diagnosis
  • Brain / pathology*
  • Brain-Derived Neurotrophic Factor / blood
  • C-Reactive Protein / metabolism
  • Cytokines / blood
  • Depressive Disorder, Major / diagnosis
  • Dopamine / metabolism
  • History, 20th Century
  • Humans
  • Isoprostanes / blood
  • Malondialdehyde / blood
  • Mental Disorders / diagnosis*
  • Mental Disorders / pathology
  • Mental Disorders / therapy
  • Mood Disorders / diagnosis*
  • Mood Disorders / therapy
  • Neopterin / blood
  • Neurofibrillary Tangles
  • S100 Calcium Binding Protein beta Subunit / blood
  • Schizophrenia / diagnosis*
  • Schizophrenia / therapy*
  • Suicidal Ideation*
  • gamma-Aminobutyric Acid / metabolism

Substances

  • Biomarkers
  • Brain-Derived Neurotrophic Factor
  • Cytokines
  • Isoprostanes
  • S100 Calcium Binding Protein beta Subunit
  • S100B protein, human
  • Malondialdehyde
  • gamma-Aminobutyric Acid
  • Neopterin
  • BDNF protein, human
  • C-Reactive Protein
  • Acetyltransferases
  • diamine N-acetyltransferase
  • Dopamine